ArticleInfection and immunity1986
Comparison of living and nonliving vaccines for Brucella abortus in BALB/c mice.
Article in Infection and immunity, 1986. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 182 citations in OpenAlex.
- Meta-Analysis and Advancement of Brucellosis Vaccinology.PloS one · 2016Pooled it
- Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates.BMC bioinformatics · 2013Pooled it
- Immunogenicity of a LipopolysaccharideVaccines · 2025Article
- Beyond survival to domination:Frontiers in microbiology · 2025Review
- Development of a Plant-Expressed Subunit Vaccine against Brucellosis.Microorganisms · 2024Article
- A TLR4 agonist liposome formulation effectively stimulates innate immunity and enhances protection from bacterial infection.Innate immunity · 2023Article
- Brucellosis: epidemiology, pathogenesis, diagnosis and treatment-a comprehensive review.Annals of medicine · 2023Review
- The Retrospective on AtypicalMicroorganisms · 2022Review
- Evaluation of Brucellosis Vaccines: A Comprehensive Review.Frontiers in veterinary science · 2022Review
- Deciphering the Molecular Basis for Attenuation ofVaccines · 2021Article
- Sustained antigen release polyanhydride-based vaccine platform for immunization against bovine brucellosis.Heliyon · 2019Article
- Article
- Protective role ofVeterinary world · 2018Article
- Brucella abortus phosphoglyceromutase and dihydrodipicolinate reductase induce Th1 and Th2-related immune responses.World journal of microbiology & biotechnology · 2018Article
- Development and trial of vaccines againstJournal of veterinary science · 2017Review
- Protection efficacy of the Brucella abortus ghost vaccine candidate lysed by the N-terminal 24-amino acid fragment (GI24) of the 36-amino acid peptide PMAP-36 (porcine myeloid antimicrobial peptide 36) in murine models.The Journal of veterinary medical science · 2016Article
- Identification of Synthetic and Natural Host Defense Peptides with Leishmanicidal Activity.Antimicrobial agents and chemotherapy · 2016Article
- Article
- Toll-Like Receptors 2 and 4 Cooperate in the Control of the Emerging PathogenFrontiers in cellular and infection microbiology · 2016Article
- Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions.The American journal of pathology · 2015Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The BALB/c mouse was selected as a model for infection with Brucella abortus on the basis of protracted nonclinical infection produced by strain 2308, virulent for cattle, and relatively rapid clearance of strain 19, an attenuated strain used to vaccinate cattle. Protection in mice vaccinated with strain 19 was compared with that obtained with nonliving vaccines at early (1 week) and later (4 weeks) intervals after challenge with strain 2308 and assessed by enumeration of B. abortus organisms in the spleen. Mice challenged 4 weeks after vaccination with strain 19 exhibited significant protection at 1 and 4 weeks postinfection (p.i.), with an increased magnitude of protection at the later time. When challenged 6 weeks after vaccination with strain 19, the level of protection diminished between 1 and 4 weeks p.i. and at the later time was not always significantly different from controls. Mice immunized 4 weeks earlier with nonliving vaccines in mineral oil with t trehalose dimycolate (TDM) and muramyl dipeptide (MDP) demonstrated patterns of protection similar to those obtained following the 6 week vaccination-challenge interval with strain 19. Vaccination with cell envelopes derived from strain 2308 produced equivalent protection at 1 week p.i. whether administered in phosphate-buffered saline, incomplete Freund adjuvant, or the TDM and MDP adjuvant. Equivalent protection also followed vaccination with strain 2308 killed whole cells, cell envelopes, or outer membrane proteins in phosphate-buffered saline or in the TDM and MDP adjuvant. The TDM and MDP adjuvant alone induced nonspecific resistance, which peaked at 1 day p.i. and was still present at 1 week p.i., although by this time its magnitude was significantly less than the protection induced by antigen combined with the adjuvant. These data, together with the results of antibody assays and passive and adoptive transfer studies, suggested that protection at 1 week p.i. could be accounted for largely by an effect of O antibodies, with T cell-mediated immune responses having a subsidiary role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.